About Kypha
Kypha is a company based in Saint Louis (United States) founded in 2009. Kypha has raised $16.76 million across 14 funding rounds from investors including HHS, Arsenal Capital Partners and Arsenal Capital Management. Kypha has completed 1 acquisition, including Biosensia. Kypha offers products and services including RapiPlex™, Comp ACT®, Assay Development, and Custom Panel Development. Kypha operates in a competitive market with competitors including HYCOR BioMedical, Exagen, Lophius Biosciences, PredictImmune and Immudex, among others.
- Headquarter Saint Louis, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kypha
Kypha offers a comprehensive portfolio of products and services, including RapiPlex™, Comp ACT®, Assay Development, and Custom Panel Development.
Enables simultaneous quantitative multiplex analysis from biological samples.
Offers quantitative single analyte measurement with minimal sample volume.
Supports bioanalytical needs for safety monitoring and diagnostics.
Creates tailored panels for specific protein analysis in research.
People of Kypha
Unlock access to complete
Unlock access to complete
Funding Insights of Kypha
Kypha has successfully raised a total of $16.76M across 14 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kypha
Kypha has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Arsenal Capital Partners and Arsenal Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Private equity investments target specialty industrials and healthcare sectors.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on Agtech and multiple sectors
|
Locked | Locked | Locked |
Investor details for Kypha
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kypha
Kypha has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Biosensia.
Investment portfolio details for Kypha
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Point-of-care in vitro diagnostics platform for immunoassays is developed.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Kypha
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Kypha
Detailed financials for Kypha
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kypha Comparisons
Peer comparison for Kypha
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kypha
Kypha operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Exagen, Lophius Biosciences, PredictImmune and Immudex, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
|
| Locked | Locked | Locked |
Diagnostic and monitoring solutions for autoimmune connective diseases are developed.
|
|
| Locked | Locked | Locked |
T-cell-based diagnostics for infectious and immune diseases are developed.
|
|
| Locked | Locked | Locked |
Tools for diagnosing immune-mediated inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of immune monitoring reagents and services for research and clinical use
|
Detailed competitors of Kypha
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kypha
Complete news archive for Kypha
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kypha
Kypha was founded in 2009.
Kypha is headquartered in Saint Louis, United States. It is registered at Saint Louis, Missouri, United States.
Kypha is a funded company, having raised a total of $16.76M across 14 funding rounds to date.
Kypha was founded in 2009 in Saint Louis, United States, and operates in the in-vitro diagnostics sector focused on inflammation and autoimmune conditions. Innovative biomarker tests are discovered, developed, and commercialized for indications such as lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The COMP ACT System is utilized to detect and quantify inflammatory status through complement-related biomarkers, enabling monitoring over time.
Kypha's top competitors include Exagen, SmartHealth and HYCOR BioMedical.
Kypha offers RapiPlex™, Comp ACT®, Assay Development, and Custom Panel Development.
Kypha has made 1 acquisition, including Biosensia.
Kypha has 7 investors. Key investors include HHS, Arsenal Capital Partners, Arsenal Capital Management, Serra Ventures, and BioGenerator Ventures.